JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McMillan, D. E.
Right arrow Articles by Hardwick, W. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McMillan, D. E.
Right arrow Articles by Hardwick, W. C.

Effects of drug discrimination history on the generalization of pentobarbital to other drugs

DE McMillan, WL Sun and WC Hardwick

Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, USA.

In pigeons trained to discriminate between pentobarbital and saline, pentobarbital, amobarbital and diazepam substituted for pentobarbital, whereas phencyclidine (PCP) substituted in part for pentobarbital and d- amphetamine, morphine and drug vehicles did not substitute. After morphine replaced pentobarbital as the training drug (group A), morphine, pentobarbital and diazepam substituted, PCP substituted in part, but not d-amphetamine, haloperidol and vehicles. After d- amphetamine replaced pentobarbital as the training drug (group B), d- amphetamine, pentobarbital and diazepam substituted, PCP substituted in part, but not haloperidol, morphine and vehicles. Next, morphine and d- amphetamine were reversed as training drugs for the two groups. In group A, morphine, d-amphetamine, pentobarbital and diazepam substituted, PCP substituted in part, but not haloperidol and vehicles. Similar effects were observed in group B. Next, birds in group A were reinforced for responses on the drug key (red key) after d-amphetamine and on the previous saline key (green key) after pentobarbital. In group B, morphine continued as the training drug for the red key, whereas responses on the green key were reinforced after pentobarbital. In group A, d-amphetamine, morphine, d-pentazocine and to some extent PCP, produced responding on the red key, whereas pentobarbital, diazepam, haloperidol and the vehicles produced responding on the green key. Similar results were obtained in group B. Finally, responses were reinforced on the green key after pentobarbital and on the red key after saline. Group B did not learn this discrimination. In group A, responding occurred on the red key after d-amphetamine, morphine, haloperidol and vehicles, in part after d-pentazocine, but not after pentobarbital, diazepam and PCP. These experiments show that drug stimuli can continue to exert stimulus control over behavior for long periods, even when training with several other drug stimuli intervenes between tests, and the experiments also show that through sequential training procedures multiple drugs can serve as discriminative stimuli for the same response, even when these drugs are from different phamacological classes.

Volume 278, Issue 1, pp. 50-61, 07/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
C. A. Bowen, B. D. Fischer, N. K. Mello, and S. S. Negus
Antagonism of the Antinociceptive and Discriminative Stimulus Effects of Heroin and Morphine by 3-Methoxynaltrexone and Naltrexone in Rhesus Monkeys
J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 264 - 273.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1996 by the American Society for Pharmacology and Experimental Therapeutics.